Kymathera Raises $80 Million Series B To Advance Cancer Drug K-1728

Kymathera has announced an $80 million Series B financing round to advance its next-generation pan-mutant selective Pi3kα inhibitor, K-1728, for the treatment of cancer and vascular malformations.